GeneNews Limited: Bringing the Blood Transcriptome to Personalized Medicine.
GeneNews Ltd is a Canada and USA-based company focused on developing and commercializing proprietary molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual's current risk for having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. GeneNews has subsidiaries in Canada and the United states. The Company's partners include JTS Health Partners and NueHealth, which are located in the United States.
About Us.
GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine. GeneNews has developed and patented the Sentinel Principle®, an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome. Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of malignancy, including those for oncology, cardiovascular, metabolic and neurological related disorders. Currently available products and services from GeneNews are: ColonSentry™, the world‘s first blood-based molecular test for colorectal cancer, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts.
GeneNews Cofounder and Chief Scientist, C-C Liew, is a recognized pioneer in the field of molecular medicine and cardiovascular genomics. He is the founding director of the Cardiovascular Genomics unit at the Brigham and Women‘s Hospital, Harvard Medical School, USA, and is a professor Emeritus at the University of Toronto, Canada. In addition, C-C Liew has been recognized with 14 Honorary Professorships by leading global insitutions including the Chinese University of Hong Kong, Peking University and Peking Union Medical College, China. GJ Liew, President and Chief Operating Officer, also serves as a director on the GeneNews Board, and is a business executive trained in molecular genetics and law. She was formerly corporate counsel to a venture capital fund and is a graduate of the University of Toronto, University of Western Ontario and the Kellogg-Schulich Schools of Business, Canada. GeneNews scientist, DJ Novak, is trained in medical genetics with a specialization in cancer genetics. He is a graduate of McGill University, Canada, and has earned multiple awards for his contribution to cancer research.
Services 🚀
GeneNews Limited (Toronto, Canada) is a molecular diagnostics company that is advancing the application of functional genomics to deliver on the promise of personalized health management. The company's lead product, ColonSentry(TM), is the world's first blood-based molecular test for colorectal cancer, currently available in Canada, China and Malaysia. ColonSentry is expected to be launched in the USA. Also currently available, is GeneNews'suite of RNA-based services: the SentinelGX(TM) Pharmacogenomic and Companion Diagnostic BloodRNA(TM) services. The company has additional 'Sentry'products in development that focus on unmet clinical needs in oncological, cardiovascular, metabolic and neurological areas. GeneNews has raised over CAN$55 million to date from private and institutional investors and has a portfolio of more than 75 issued or pending patents.
CEO
GeneNews Inc. was founded in 1998 by Choong-Chin Liew, an expert in cardiovascular genomics and pioneer in the emerging field of molecular medicine. The company's assets were purchased by ChondroGene Limited (TSXV:CDG), a publicly listed functional genomics company, in 2003. The company was subsequently listed on the Toronto Stock Exchange (TSX:GEN) in October 2006, as GeneNews Limited
GeneNews Limited: bringing the blood transcriptome to personalized medicine ✨
GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine. GeneNews has developed and patented the Sentinel Principle(®), an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome. Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of malignancy, including those for oncology, cardiovascular, metabolic and neurological related disorders. Currently available products and services from GeneNews are: ColonSentry™, the world's first blood-based molecular test for colorectal cancer, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts.
Empowering individuals by improving local-marketing skills
Clear and persuasive description of the service you provide prevents page-visitors from bouncing directly after they landed on this page.
Location
GeneNews is headquartered in Toronto, Canada, with a global staff people. The Toronto site comprises a 10,000 square foot, ISO9001-2008 certified facility, including 5000 square feet of custom-built dedicated laboratory space. In addition, GeneNews has established an ISO17025-certified research and development facility in Penang, Malaysia. This site has gained the support of the Malaysian Ministry of Health, to augment the company's pipeline development capacity. GeneNews has built key resources including: a biobank of more than 17,000 human whole-blood/RNA samples with associated clinical information; databases of Affymetrix ® (CA, USA) whole-transcriptome data and proprietary data-mining processes that are available to support pharmaceutical partners in their biomarker discovery and validation efforts.
© Copyright 1997-2024, GeneNews LTD., All rights reserved